Abaloparatide Injection

Before receiving abaloparatide injection,

• tell your doctor and pharmacist if you are allergic to abaloparatide, any other medications, or any of the ingredients in abaloparatide injection. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
• tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
• tell your doctor if you have or have ever had any condition that causes you too have too much calcium in the blood, hyperparathyroidism (condition in which the body produces too much parathyroid hormone [natural substance needed to control the amount of calcium in the blood]), or kidney stones.
• you should know that abaloparatide injection should only be used by women once they have passed menopause and, therefore, cannot become pregnant or breastfeed. Abaloparatide injection should not be used during pregnancy or while breastfeeding.

Unless your doctor tells you otherwise, continue your normal diet.

Use the missed dose as soon as you remember it that day. However, if the day has already passed, skip the missed dose and continue your regular dosing schedule. Never inject more than one dose per day.

In a clinical study, accidental overdose was reported in a patient who received 400 mcg in one day (5 times the recommended clinical dose); dosing was temporarily interrupted. The patient experienced asthenia, headache, nausea, and vertigo. Serum calcium was not assessed on the day of the overdose, but on the following day the patient's serum calcium was within the normal range. The effects of overdose may include hypercalcemia, nausea, vomiting, dizziness, tachycardia, orthostatic hypotension, and headache.

Overdosage Management

There is no specific antidote for TYMLOS. Treatment of suspected overdose should include discontinuation of TYMLOS, monitoring of serum calcium and phosphorus, and implementation of appropriate supportive measures, such as hydration. Based on the molecular weight, plasma protein binding and volume of distribution, abaloparatide is not expected to be dialyzable.